LDS/Medical Tests/Gastrointestinal Stromal Tumor Gene Mutation Panel, NGS

Gastrointestinal Stromal Tumor Gene Mutation Panel, NGS

Gastrointestinal stromal tumors (GIST) are mesenchymal neoplasms that may arise in the stomach (60%), small intestine (30%), and less frequently from other parts of the GI tract (10%). Mutations in KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) and PDGFRA (platelet-derived growth factor receptor alpha polypeptide) genes are crucial events in the pathogenesis of GIST. Molecular genetic profiling of these tumors has gained attention as specific treatments targeting KIT and PDGFRA mutation have become available (e.g., imatinib, sunitinib). These genes encode protein that belong to the receptor tyrosine kinase class III family, which are involved in the regulation of cell growth, proliferation, adhesion, migration, differentiation, and apoptosis. The gastrointestinal stromal tumors gene mutation panel is targeted next-generation sequencing to evaluate mutation in KIT (exon 2, 9, 10, 11, 13, 14, 15, 17, 18) and PDGFRA (exons 12, 14, 15, 18) genes.

About 85% of GIST are associated with the somatic mutation in the KIT and 5% in the PDGFRA gene. The most common mutation of KIT is located in exon 11 (70%) which encodes the juxtamembrane domain of the receptor, followed by the mutation in exon 9 (10%) encoding the extracellular domain of KIT and mutation in exons 13 and 17 (1% - 2%) encoding the ATP-binding pocket and the activation loop, respectively. Mutations in exon 18 comprise the majority (>80%) of the PDGFRA mutations. Rarely, mutations in exons 12 and 14 of the PDGFRA gene have also been reported. Most of these mutations are somatic but rarely familial GIST syndrome have also been reported.

Specific mutations can predict the response of primary GIST or secondary resistant tumor to KIT/PDGFRA tyrosine kinase inhibitors. Approximately, 90% of patients with mutation in exon 11 of the KIT gene respond well to imatinib, whereas only 50% of patients with mutation in exon 9 respond with imatinib. PDGFRA mutations in exon 18 are mostly point mutations (Aps842Val) resulting in imatinib resistance. About 10% - 15% of patients with GIST are negative to the mutations in KIT or PDGFRA genes (wild-type GIST). These patients should be considered for BRAF and SDH gene mutation testing.

  • Aid in the diagnosis, prognosis and management of gastrointestinal stromal tumors
  • Diagnosis of familial Gastrointestinal stromal tumors syndrome (rare)
  • Positive: Mutation in the KIT and/or PDGFRA gene
  • Negative: No mutation in the KIT and/or PDGFRA gene

Negative for mutation in the KIT and/or PDGFRA gene

Gene target based Next-Generation Sequencing, Sanger sequencing.

Formalin-fixed, paraffin-embedded (FFPE) tissue block, Tissue slide, Cytology slide.

Stability

  • Ambient: Indefinitely
  • Refrigerated: Indefinitely
PDGFRA Mutation Analysis, KRAS Gene Mutation Analysis, BRAF Mutation Analysis, NRAS Gene Mutation Analysis, Immunohistochemical staining (CD117, DOG1, SDHB), Cancer Antigen (CA)-19-9, Fine Needle Aspiration Biopsy.
2-4 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login